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tomography (CBCT) images in patients with liver metastases. Materials and Methods In this IRB-
approved retrospective single-center study 36 patients with a total of 104 liver metastases (56 % male,
mean age 61.1 ± 13 years) underwent CBCT prior to TARE and follow-up imaging 6 months after
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A B S T R A C T   
Purpose: To investigate the potential of texture analysis and machine learning to predict treatment response to 
transarterial radioembolization (TARE) on pre-interventional cone-beam computed tomography (CBCT) images 
in patients with liver metastases. 
Materials and Methods: In this IRB-approved retrospective single-center study 36 patients with a total of 104 liver 
metastases (56 % male, mean age 61.1 ± 13 years) underwent CBCT prior to TARE and follow-up imaging 6 
months after therapy. Treatment response was evaluated according to RECIST version 1.1 and dichotomized into 
disease control (partial response/stable disease) versus disease progression (progressive disease). After target 
lesion segmentation, 104 radiomics features corresponding to seven different feature classes were extracted with 
the pyRadiomics package. After dimension reduction machine learning classifications were performed on a 
custom artificial neural network (ANN). Ten-fold cross validation on a previously unseen test data set was 
performed. 
Results: The average administered cumulative activity from TARE was 1.6 Gbq (± 0.5 Gbq). At a mean follow-up 
of 5.9 ± 0.8 months disease control was achieved in 82 % of metastases. After dimension reduction, 15 of 104 (15 
%) texture analysis features remained for further analysis. On a previously unseen set of liver metastases the 
Multilayer Perceptron ANN yielded a sensitivity of 94.2 %, specificity of 67.7 % and an area-under-the receiver 
operating characteristics curve of 0.85. 
Conclusion: Our study indicates that texture analysis-based machine learning may has potential to predict 
treatment response to TARE using pre-treatment CBCT images of patients with liver metastases with high 
accuracy.   
1. Introduction 
Transarterial radioembolization (TARE) represents a valuable treat-
ment option in unresectable metastatic liver disease, especially with 
liver-dominant tumor burden [1]. In TARE, Yttrium-90-microspheres 
(90Y-microspheres) are applied via a catheter into the hepatic artery 
leading to an accumulation in liver metastases with resulting 
radiation-induced cell death [2]. As TARE is a costly and highly 
demanding therapy requiring a multi-disciplinary team including 
interventional radiologists, oncologists and nuclear medicine specialists, 
careful patient selection is crucial. 
Previous studies have investigated the value of pre-treatment 
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imaging for the prediction of tumor response after TARE. Consistent 
with the idea of higher 90Y-microspheres accumulation in hypervascular 
metastases, some studies showed a favorable outcome of patients having 
liver metastases showing high arterial perfusion as quantified in an 
absolute way with computed tomography (CT) perfusion [3,4]. In 
contrast, another study [5] found no difference in survival after TARE 
between metastases classified as either hypo- or hypervascular on 
pre-treatment imaging based on a subjective and purely qualitative 
grading system for tumor vascularity. In addition, the pattern of 
99mtechnetium labelled macroaggregated albumin (99mTc-MAA) uptake 
in liver metastases failed to predict tumor response after TARE [6,7]. 
Radiomics is an emerging field in medical imaging enabling the 
objective assessment of tumor heterogeneity by extracting quantitative 
imaging features which are imperceptible to the human eye [8]. As 
tumor heterogeneity plays a crucial role in tumor growth and metasta-
ses, several recent studies focused on radiomic feature-based texture 
analysis of tumors showing that texture analysis was able to predict 
treatment response and prognosis using imaging data from CT, magnetic 
resonance (MR) imaging and positron emission tomography (PET) in 
several entities [9–11]. The application of texture analysis and machine 
learning in interventional oncology have been studied in patients who 
underwent transarterial chemoembolization (TACE) for hepatocellular 
carcinoma with promising results [12–15], and one study applied 
texture analysis to pre-TARE CT images in patients with chol-
angiocarcinoma [16]. 
The purpose of this study was to investigate the potential of texture 
analysis and machine learning to predict treatment response to TARE on 
pre-interventional cone-beam CT (CBCT) images in patients with liver 
metastases. 
2. Materials and methods 
This retrospective study was approved by the local ethics committee. 
Written informed consent requirement was waived. 
2.1. Patients 
Between January 2010 and May 2018, a total of 214 patients with 
liver metastases underwent TARE in our single tertiary referral center. 
178 patients were excluded because of missing or incomplete imaging 
follow-up six months after TARE. Thus, the final study population con-
sisted of 36 patients with a total of 104 analyzed liver metastases (55.6 
% male, mean age 61.1 ± 13 years), who underwent CBCT prior to TARE 
and follow-up imaging 6 months after therapy. Table 1 summarizes 
patient demographics and the etiology of encountered liver metastases. 
2.2. Treatment planning: angiography and cone-beam CT 
In a first step, in accordance with current guidelines [1], all patients 
underwent catheter angiography of the hepatic vasculature for treat-
ment planning. All interventions were performed in a fully equipped 
angiography suite (ARTIS zeego and ARTIS pheno; Siemens Healthi-
neers, Erlangen, Germany). In addition to standard digital subtraction 
angiography (DSA) CBCT was routinely performed. 
All CBCT were standardized with an injection protocol of 36 mL 50/ 
50 dilution of contrast media (Ultravist 370, 370 mg iodine/mL; Bayer 
Schering Pharma, Berlin, Germany) and sodium chloride 0.9 % at 2 mL/ 
s with a 10 s scan delay. Injection was performed through a 2.7Fr 
microcatheter placed either in the proper hepatic artery, right or left 
hepatic artery as appropriate. A full 200 degree rotation took 7 s. A fixed 
tube voltage of 125 kV and a current-time-product of 345–360 mA s 
were used. Images were reconstructed with a slice width of 4 mm and an 
increment of 3 mm in axial and coronal plane. 
After assessment of the hepatic vasculature anatomy coil emboliza-
tion of all nonhepatic arterial flow was performed (especially gastro-
duodenal and right gastric artery) if required. Treatment was then 
simulated by injection of 99mTc-MAA through the microcatheter placed 
in the proper hepatic artery, left or right hepatic artery, respectively. 
Immediately after diagnostic angiography, single-photon emission CT 
was performed to evaluate for hepatopulmonary shunting and extra-
hepatic non-targed accumulation of 99mTc-MAA. 
2.3. Transarterial radioembolization 
TARE was performed using 90Y-microspheres (SIR-Spheres; SIRTeX 
Medical Limited, Lane Cove, Australia) administered into the appro-
priate hepatic artery as defined during diagnostic angiography. Dose 
calculation was done using the body surface area method [17]. 
2.4. Morphologic treatment response evaluation 
Follow-up imaging consisted of CT (at least in portal venous phase) 
of the liver in 25 patients (69.4 %) and MR imaging with extracellular 
contrast agent (Dotarem®, Guerbet AG, Zurich, Switzerland) in 11 pa-
tients (30.6 %). Treatment response was evaluated according to RECIST 
version 1.1 [18]. A commercially available software was used to assess 
tumor progression (mint Lesion, Version 1.82; Mint Medical GmbH, 
Heidelberg, Germany). 
First, three target metastases (104 metastases in total) were defined 
in pre-TARE CBCT in each patient. For all lesions, maximum diameter 
change between CBCT and post-TARE follow-up imaging at 6 months 
were recorded and response according to RECIST version 1.1 was 
calculated for each lesion independently. Complete response (CR), 
partial response (PR) and stable disease (SD) were defined as disease 
control. Progressive disease (PD) was defined as disease progression 
(Fig. 1). 
2.5. Texture analysis 
Texture features are derived from pre-treatment CBCT images by 
applying different filters to quantitatively assess these images. The 
image characterization is based on the pixel intensities within a region- 
Table 1 
Patient characteristics stratified by treatment response.   
All SD/PR PD p- 
value 
Total patients, n (%) 36 (100) 32 (88.9) 4 (11.1)  







Male, n (%) 20 
(55.6) 
17 3 0.406 
Female, n (%) 16 
(44.4) 
15 1   
Tumor entity     
Neuroendocrine tumor, n (%) 9 (25) 9 0  
Gastrointestinal tract, n (%) 7 (19.4) 7 0 
Melanoma, n (%) 5 (13.9) 5 0 
Pancreas, n (%) 3 (8.3) 3 0 
Mamma, n (%) 3 (8.3) 2 1 
Others, n (%) 9 (25) 6 3  
Pre-TARE treatment     
Chemotherapy, n (%) 30 (83.3) 27 3 0.635 
Operation, n (%) 6 (16.7) 6 0 0.343 
Radiotherapy, n (%) 3 (8.3) 3 0 0.522 
Local intervention, n (%) 3 (8.3) 3 0 0.522 
In-hospital outcome     
Complications, n (%) 4 (11.1) 3 1 0.349 
In-hospital mortality, n (%) 0 (0)    
Follow-up period (months), mean 
± SD 
5.9 ±
0.8 5.9 ± 0.8 
6.2 ±
0.9 0.504 
SD = Stable disease; PR = Partial response; PD = Progressive disease. 
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of-interest. 
To do so, CBCT images were stored in the Digital Imaging and 
Communications in Medicine (DICOM) format. The images were post- 
processed with an in-house MATLAB routine, as described previously 
[19]. All images were subsequently loaded into the open-source soft-
ware platform 3D Slicer with the pyradiomics extension [20]. 
Two readers (T.S. and M.M.; 1 and 6 years of experience in radiology, 
respectively) manually segmented the target lesions prior to treatment 
on axial slices. Intensity discretization was performed to a bin width of 
25. Graylevel co-occurrence matrix (GLCM) features were computed at 4 
inter-pixel distances. Then 104 radiomics features were extracted with 
the pyRadiomics package implemented into 3D Slicer. Most features are 
in accordance with those described in the Imaging Biomarker Stan-
dardization Initiative (IBSI). Radiomic features corresponded to seven 
different feature classes: First-order statistics/histogram matrix, shape- 
based features, gray-level co-occurrence matrix (GLCM), gray-level 
run length matrix (GLRLM), gray-level size zone matrix (GLSZM), 
neighboring gray tone difference matrix (NGTDM), and gray-level 
dependence matrix (GLDM) [21]. 
2.6. Dimension reduction 
In order to reduce overfitting, dimension reduction was performed 
on the calculated texture analysis features (TA features). In a first 
instance, all texture features were normalized. Afterwards those TA 
features with decreased interrater-reproducibility, defined by an 
intraclass-correlation coefficient (ICC) of < 0.8 as previously shown 
[22], were discarded from further analysis. 
2.7. Machine learning 
For the outcome classification patients were dichotomized into a 
disease control (PR / SD) and disease progression (PD) group according 
to RECIST 1.1 [18]. Machine learning classifications were computed 
using open source software (WEKA, University of Waikato, Waikato, 
New Zealand). The classification task was performed on a training 
dataset of 83 metastases using a custom artificial neural network (ANN) 
based on Multilayer Perceptron with a batch size of 100, 2 hidden layers 
(nodes 5, 10), a learning rate of 0.4, a momentum of 0.22 and 4000 
Epochs. The results were 10-fold cross-validated. The performance 
metrics of the ANN, performed on an unseen test dataset of 21 metas-
tases, included sensitivity, specificity, precision, recall, F-measure, and 
the area-under-the-curve (AUC) from receiver operating characteristics 
(ROC) analysis. 
Fig. 2 summarizes the process of texture analysis feature extraction 
and machine learning based outcome prediction. 
2.8. Statistical analysis 
For descriptive data mean values and standard deviations are pro-
vided. Continuous variables were compared using the independent two- 
sample t-test or Mann-Whitney test, respectively. Categorical variables 
were compared using the Chi-squared test. A two-tailed p-value of less 
than 0.05 was considered significant. Statistical analyses and plots were 
performed with a commercially available software (IBM, SPSS® Statis-
tics v. 25, Chicago, IL). 
3. Results 
In total, 104 liver metastases of 36 patients (55.6 % male) were 
included for analysis. The mean size of liver metastases was 3.3 ± 2.2 cm 
in diameter. 
Mean time interval between treatment planning and TARE was 18.4 
± 16.9 days. 90Y-microspheres were administered through the proper 
hepatic artery in 15 patients (panhepatic 41.7 %), right hepatic artery in 
18 patients (right lobe 50 %) and left hepatic artery in 3 patients (left 
lobe 8.3 %) with an average cumulative activity of 1.6 Gbq (± 0.5 Gbq). 
3.1. Response to TARE 
At a mean follow-up of 5.9 ± 0.8 months, 57 (54.8 %) metastases 
showed stable disease, 28 (26.9 %) partial response and 19 (18.3 %) 
progressive disease. Accordingly, the disease control rate was 81.7 %. 
In-hospital mortality was 0%. Minor complications were observed in 
four patients (11.1 %): Mild rash after 90Y-microspheres infusion, right 
upper quadrant pain, nausea, and access site hematoma. Fig. 3 shows 
examples of different treatment responses. 
3.2. Dimension reduction 
After dimension reduction 15 out of 104 (14.5 %) TA features 
remained for further analysis, depicted in Table 2. 14 out of 15 (93.3 %) 
TA features were derived from the GLCM. 
Fig. 1. Patient flow chart.  
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3.3. Prediction of liver metastases response to TARE 
After 10-fold cross validation the Multilayer Perceptron ANN yielded 
a Sensitivity of 94.2 %, a Specificity of 67.7 %, a Precision of 0.8, a 
Recall of 0.84, an F-Measure of 0.81, and an AUC in ROC of 0.85 on the 
previously unseen test dataset of 21 metastases (Fig. 4). 
4. Discussion 
The present study indicates that machine learning based on selected 
texture analysis features could be a useful tool to predict treatment 
response based on pre-treatment CBCT images in patients with liver 
metastases undergoing transarterial radioembolization. 
The herein used state of the art texture analysis tool is an open source 
software, developed to increase feature computation reliability and 
reproducibility. This tool has been used and validated in several radio-
mics studies across different imaging modalities and medical conditions 
[19,22]. 
Interestingly, after dimension reduction, 14 out of the 15 remaining 
texture analysis features used in the machine learning algorithm derived 
from the GLCM. The GLCM takes into account the spatial relationship of 
pixels. It characterizes the texture of an image by calculating how often 
pairs of pixels interconnected by a specified spatial relationship and 
specific values occur in an image. As part of this computational process, 
a matrix is calculated, from which statistical measures can then be 
extracted. 
Similar to our approach, Park et al. [23] investigated texture analysis 
features on pre-treatment CT images in patients with hepatocellular 
carcinoma undergoing TACE. In treatment responders the hepatocellu-
lar carcinomas showed higher GLCM moments and lower homogeneity. 
The authors concluded that these features might reflect high tumor 
heterogeneity and most importantly the presence of intra-tumoral 
angiogenesis, which evidently renders tumors more susceptible to an 
intraarterial therapy such as TACE [23]. 
Other studies investigating the ability of texture analysis have found 
comparable results. In patients with hepatocellular carcinomas under-
going TACE texture analysis features were able to determine, which 
patient may benefit from surgery versus TACE or TACE alone versus 
TACE plus systemic chemotherapy [24,25]. However, these studies used 
different machine learning classifiers and strategies for dimension 
reduction. 
For transarterial radioembolization there is only one radiomics study 
by Mosconi et al. [16] where texture analysis features were analyzed on 
pre-treatment CT images to predict treatment response. However, the 
study only included patients with intrahepatic cholangiocarcinoma. In 
treatment responders the intrahepatic cholangiocarcinomas showed 
higher mean histogram values, corresponding to higher contrast uptake 
in the arterial phase, and a more homogeneous distribution. More pre-
cisely, lower kurtosis, GLCM contrast, GLCM dissimilarity and higher 
GLCM homogeneity and GLCM correlation were found. 
In the early days of texture analysis, due to inherent image noise of 
CT images, there were concerns that the extracted texture features might 
only reflect image noise instead of true biological heterogeneity of the 
tumor. This problem was overcome with image filtration techniques that 
are able to reduce image noise [8]. In our study we decided to use 
cone-beam CT images from the treatment planning procedure prior to 
TARE as the pre-TARE imaging workup was extremely heterogeneous 
between patients. Specifically, most patients were referred from external 
hospitals specifically for the procedure and thus, some had initially 
received MRI workup, while others had undergone CT scans, often from 
various vendors and with various scanning protocols. In contrast, CBCTs 
were performed in a standardized manner with identical reconstruction 
protocols, which made them comparable between all patients over a 
long period-of-time. In general, CBCT images provide higher spatial 
resolution with reduced contrast resolution compared to multidetector 
CT images [26]. Nevertheless, they are susceptible to movement arti-
facts and exhibit higher image noise which could be problematic for 
texture analysis. Two previous studies on non-small cell lung cancer 
patients have however shown that texture analysis on CBCT images is 
robust and reproducible [27,28]. 
As texture analysis features are abstract numbers and thus difficult to 
implement into standard image interpretation artificial intelligence 
could be used to close the gap between overwhelming imaging data and 
decision making in oncologic patients. More precisely, the extracted 
texture analysis features showing differences between responders and 
non-responders could be used for supervised machine learning. Specif-
ically, an artificial neural network initially trained on the extracted 
texture analysis features and the corresponding treatment response 
could then be used for outcome prediction on new data sets [29–31]. 
To our knowledge this is the first study to investigate the potential of 
texture analysis based machine learning on pre-treatment imaging of 
patients with liver metastases undergoing TARE. Our model achieved a 
good accuracy for differentiating disease control (PR / SD) from disease 
progression (PD) with a sensitivity of 94.2 %, a specificity of 67.7 % and 
an AUC in ROC of 0.85 (Fig. 4). 
Few studies in interventional oncology have yet investigated the 
ability of machine learning to predict tumor response or survival with 
most studies focusing on patients with hepatocellular carcinoma un-
dergoing TACE [12–15]. 
Abajian et al. [13] trained an ANN with clinical data, pre-treatment 
imaging patterns (relative tumor signal intensity and number of tumors) 
and therapeutic features (conventional TACE or not and systemic 
Fig. 2. Image post-processing flow 
chart for texture analysis based 
machine-learning to predict treatment 
response after transarterial radio-
embolization (TARE). On cone-beam CT 
(CBCT) images a region of interest is 
drawn around the selected metastases. 
Texture analysis features are extracted. 
The artificial neural network (ANN) is 
trained with the extracted texture anal-
ysis features of 83 liver metastases. 
Machine learning based prediction of 
tumor response after TARE on an un-
seen image set of 21 metastases is 
performed.   
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chemotherapy or not) rather than with texture analysis features. This 
ANN yielded a sensitivity and specificity of 62.5 % and 82.1 %, 
respectively for treatment response prediction. A similar approach was 
used by Mähringer et al. [14] who trained the ANN with clinical, lab-
oratory and imaging parameters which are used in current risk scores to 
predict 1-year survival after TACE. With an AUC of 0.77, this ANN 
performed better than traditional scoring systems in predicting 1-year 
survival after TACE. 
Only Morshid et al. [12] chose a texture analysis based approach for 
pre-TACE CT images in combination with BCLC stage thereby achieving 
an accuracy rate for response prediction of 74.2 %. These studies suggest 
that it might be useful to add clinical parameters to the texture analysis 
features in an effort to further improve the accuracy of the machine 
learning algorithm. 
Fig. 3. Examples of metastases in pre-treatment cone-beam CT 
(left column) and follow-up computed tomography scans after 
transarterial radioembolization (right column). All encoun-
tered treatment responses according to RECIST 1.1. are illus-
trated: “partial response” (first row), “stable disease” (second 
row) and “progressive disease” (third row). Pre-treatment 
metastases are labeled by white arrows, post-TARE metasta-
ses by white dotted arrows and newly appeared metastases by 
white stars.   
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Supported by our results, all published studies investigating machine 
learning based outcome prediction on pre-treatment images so far 
reason that ANNs may help to identify patients who will benefit from 
interventional oncologic treatments. Ultimately, this may result in better 
patient selection and avoid unnecessary treatments. Furthermore, it may 
be possible to detect metastases within a patient that are potentially less 
responsive to TARE. These identified metastases could be treated with 
combined minimally invasive therapies, namely additional percuta-
neous thermoablative procedures. Further studies have to be conducted 
to validate these assumptions. 
There are major limitations we must acknowledge. First, we 
analyzed a highly heterogeneous patient population with liver metas-
tases from different primaries. Second, the sample size of 36 patients is 
fairly small. This limitation was overcome by analyzing multiple me-
tastases per patient, resulting in 104 analyzed metastases. However, this 
carries the risk of biasing the results as no external validation was per-
formed. Furthermore, with a disease control rate of 81.7 % there was a 
disequilibrium in the training set, as only few cases of disease progres-
sion were available to train the ANN. Finally, it must be emphasized that 
due to the small number of patients and heterogeneous tumor entities, 
ultimately no conclusions can be drawn that allow generalizable results 
between tumor entities. 
In conclusion, our study indicates that texture analysis-based ma-
chine learning may has potential to predict treatment response to TARE 
using pre-treatment CBCT images of patients with liver metastases with 
high accuracy. 
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